QPW
CRSP icon

Quantum Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Quantum Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Buy
6,300
+1,400
+29% +$73.8K 0.09% 124
2025
Q4 		$257K Buy
+4,900
New +$293K 0.08% 141

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quantum Private Wealth's CRSP Position: Q1 2026 in Review

Quantum Private Wealth increased its CRISPR Therapeutics (CRSP) stake by 29% in Q1 2026, buying an estimated $73.8K and bringing the position to 6,300 shares worth $300K. The position accounts for 0.09% of the portfolio, ranked #124.

Quantum Private Wealth first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Quantum Private Wealth held 6,300 shares of CRISPR Therapeutics worth $300K as of Q1 2026.
  • Quantum Private Wealth bought 1,400 CRISPR Therapeutics shares in Q1 2026, an estimated $73.8K.
  • CRISPR Therapeutics made up 0.09% of Quantum Private Wealth's portfolio in Q1 2026, its #124 holding.
  • Quantum Private Wealth first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Quantum Private Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.